ArticleRadiation oncology (London, England)2025
Stereotactic body radiotherapy for single and multiple early-stage non-small cell lung cancer in patients aged ≥ 80 years.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment Outcomes for Elderly Patients over the Age of 70 with Early-Stage Peripheral Non-Small Cell Lung Cancer Who Were Treated with Stereotactic Body Radiation Therapy (SBRT) at a Total Dose of 55 Gy in Four Fractions: A Single-Institution Retrospective Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer primarily affects elderly individuals and is the leading cause of cancer-related death in people aged 80 years and older. In addition, the incidence of multiple primary lung cancer (MPLC) is increasing worldwide. Although surgery is recommended as the standard of care, many elderly patients are considered medically unsuitable, or they refuse surgery. The role of stereotactic body radiotherapy (SBRT) as an alternative treatment option for these elderly patients, particularly those with multiple primary lung cancer, has not been fully elucidated. Therefore, the aim of this study was to report the outcome and toxicities associated with SBRT for histologically confirmed early-stage non-small cell lung cancer (NSCLC) and synchronous and metachronous multiple primary lung cancer in patients aged ≥ 80 years.
methodsThis retrospective study included 118 patients aged ≥ 80 years with a total of 141 SBRT-treated primary lung cancers (19 patients with MPLC). We assessed local control (LC), progression-free survival (PFS), overall survival (OS) and cancer-specific survival (CSS). We further evaluated toxicities and factors impacting therapeutic efficacy.
resultsThe median follow-up after SBRT was 47 months (range 3-169 months). The LC rate was 96.2% (95% CI: 90.1 to 98.6%) two years and 86.4% (71.8 to 93.8%) five years after SBRT for NSCLC/MPLC. The PFS and OS rates were 67.0% (57.4 to - 74.9%) and 74.7% (65.4 to - 81.1%), respectively, after two years and 24.7% (14.5 to 35.6%) and 30.2% (19.4 to 41.7%), respectively, after five years. The CSS rate was 88.6% (80.3-93.6%) at two years and 76.6% (61.4-86.4%) at 5 years after SBRT. Age and the Charlson Comorbidity Index score were found to be independent predictors of OS and PFS. Predictors other than these patient-related factors could not be identified. Toxicities higher than Grade 2 after SBRT of NSCLC and MPLC were not observed.
conclusionThis study emphasises the efficacy and safety of SBRT in the treatment of early-stage NSCLC in patients aged ≥ 80 years, including those with MPLC. SBRT proves to be an appropriate treatment modality for this frail patient group, as it provides favourable LC and CSS rates with low toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.